Generation of virus-like particles and use as panfilovirus vaccines
OwnerSina Bavari, M. Javad Aman +3inventors
InventorsSina Bavari, M. Javad Aman, Alan L. Schmaljohn, Kelly L. Warfield, Dana Swenson
Life of this patent
Estimating the term…
Abstract
In this application are described filovirus-like particles for both Ebola and Marburg and their use as a diagnostic and therapeutic agent as well as a filovirus vaccine. Also described is the association of Ebola and Marburg with lipid rafts during assembly and budding, and the requirement of functional rafts for entry of filoviruses into cells.
Claims48
A filovirus virus like particle, VLP, comprising filovirus envelope glycoprotein, GP, and filovirus matrix protein, VP40.
A filovirus VLP, produced by expressing in a cell a polynucleotide encoding filovirus envelope glycoprotein, GP, and filovirus matrix protein, VP40 such that said polynucleotide is expressed and said VLP is produced.
A method for inhibiting the association of a filovirus envelope glycoprotein GP with lipid rafts, comprising inhibiting palmitoylation at cysteine residues 670 and 672 of said GP.
A method for preventing filovirus trafficking into and out of a cell comprising disrupting lipid rafts of said cell.
A method for preventing filovirus trafficking said method comprising introducing to a cell cholesterol synthesis inhibitors.
An Ebola VLP-producing cell comprising a mammalian cell expressing Ebola GP and VP40.
A method for inhibiting Ebola virus infection in a cell comprising administering to said cell lipid raft-disrupting agents.
A Marburg VLP-producing cell comprising a mammalian cell expressing Marburg GP and VP40.
Dependencies are inferred from the claim text.